key: cord-0843576-jlnm46nh authors: Martin-Sancho, Laura; Lewinski, Mary K.; Pache, Lars; Stoneham, Charlotte A.; Yin, Xin; Pratt, Dexter; Churas, Christopher; Rosenthal, Sara B.; Liu, Sophie; De Jesus, Paul D.; O’Neill, Alan M.; Gounder, Anshu P.; Nguyen, Courtney; Pu, Yuan; Oom, Aaron L.; Miorin, Lisa; Rodriguez-Frandsen, Ariel; Urbanowski, Matthew; Shaw, Megan L.; Chang, Max W.; Benner, Christopher; Frieman, Matthew B.; García-Sastre, Adolfo; Ideker, Trey; Hultquist, Judd F.; Guatelli, John; Chanda, Sumit K title: Functional Landscape of SARS-CoV-2 Cellular Restriction date: 2020-09-30 journal: bioRxiv DOI: 10.1101/2020.09.29.319566 sha: 4811915ed1f1a4fbed998df9420147d8665e08fa doc_id: 843576 cord_uid: jlnm46nh A deficient interferon response to SARS-CoV-2 infection has been implicated as a determinant of severe COVID-19. To identify the molecular effectors that govern interferon control of SARS-CoV-2 infection, we conducted a large-scale gain-of-function analysis that evaluated the impact of human interferon stimulated genes (ISGs) on viral replication. A limited subset of ISGs were found to control viral infection, including endosomal factors that inhibited viral entry, nucleic acid binding proteins that suppressed viral RNA synthesis, and a highly enriched cluster of ER and Golgi-resident ISGs that inhibited viral translation and egress. These included the type II integral membrane protein BST2/tetherin, which was found to impede viral release, and is targeted for immune evasion by SARS-CoV-2 Orf7a protein. Overall, these data define the molecular basis of early innate immune control of viral infection, which will facilitate the understanding of host determinants that impact disease severity and offer potential therapeutic strategies for COVID-19. 4 regulate endoplasmic reticulum-associated protein degradation (ERAD), lipid membrane composition, 115 and vesicle transport. Among these was BST2, found to inhibit viral egress and to be antagonized by 116 SARS-CoV-2 accessory protein Orf7a to rescue virion release. The identification of the ISG subset that 117 direct the antiviral activity of IFN illuminates the molecular and genetic determinants of early immune 118 regulation that contribute to COVID-19 outcome, and provide attractive specific targets for therapeutic 119 intervention. To define the cellular effectors that act to limit SARS-CoV-2 infection, we first sought to 124 determine which genes are activated upon IFN stimulation (hereafter referred to as ISGs) in disease-125 relevant cell types. Human tracheobronchial epithelial (HTBE) and human alveolar epithelial A549 cells CoV-2 infection (Blanco-Melo et al., 2020; Emanuel et al., 2020; Overmyer et al., 2020; Sun et al., To understand how these antiviral effectors impact viral replication, a selected subset of ISGs 195 were tested for their ability to inhibit specific stages of the SARS-CoV-2 infectious cycle. Firstly, we 196 adopted a pseudotyped VSV expressing SARS-CoV-2 S protein (VSV-S-luciferase) to measure viral 197 entry (Fig 3A, diagram) . Then we assessed viral RNA replication by measuring viral RNA at 8 h post-198 infection (Fig 3B) . Lastly, we infected naïve cells with viral supernatants that were collected at 18 h 199 post infection to assess late stage activity, encompassing viral translation and egress (Fig 3C) . These 200 experimental data were integrated with available bioinformatic resources that provided information on 201 subcellular localization and known function to establish a predictive map of the impact of these ISGs on 202 the SARS-CoV-2 infectious cycle (Fig 4) . Entry of SARS-CoV-2 into the host cell is facilitated by viral S protein binding to the ACE2 205 cellular receptor promoting endocytosis. Upon entry, SARS-CoV-2 viral particles escape the endosome 206 to initiate viral replication (Hoffmann et al., 2020) . Six ISGs reduced entry of the pseudotyped VSV-S 207 by more than 50%, including LY6E, CLEC4D, UBD, ELF1, FAM46C and REC8 (Fig 3A, 4) . LY6E was 208 previously demonstrated to restrict SARS-CoV-2 entry by inhibiting viral S protein fusion at the 209 membrane (Pfaender et al., 2020) . CLEC4D is an integral membrane protein that acts as an endocytic 210 receptor and has been linked to inhibition of bacteria uptake (Wilson et al., 2015) . Another ISG affecting 211 viral entry was UBD/FAT10, which is recruited to the incoming Salmonella-containing vacuole (SCV) 212 together with the autophagy cargo receptor p62 (Spinnenhirn et al., 2014) , and these serve as signals for 213 lysosomal targeting and pathogen clearance. Since these ISGs have been reported to impact endo-214 lysosomal function, it is possible that they interfere with SARS-CoV-2 entry by impeding low pH-215 dependent entry or endosomal escape. Finally, the transcription factor ELF1 was also found to affect 216 viral entry. ELF1 governs a complex transcriptional program of over 300 genes that are largely distinct Following SARS-CoV-2 release into the cytosol, expression of the replicase gene from the viral 222 genomic RNA generates non-structural proteins (nsp). These nsps coordinate the assembly of the 7 replication (>50% inhibition) (Fig 3B) , including IFIT3, SPATS2L, DNAJC6, RGSS2, LOC152225, as 226 well as ZBP1 and B4GALT5, which were found to be core components of the cell death and sphingolipid 227 metabolism networks shown in Fig 2B, E. The IFIT-family includes five members (IFIT1, IFIT1B, IFIT2, IFIT3, and IFIT5), which 230 prevent active viral RNA replication by detection and sequestering of single-stranded 5′-ppp or 2′O-231 unmethylated RNA (Metz et al., 2013) . In this study, we identified three members of this family, IFIT1, 232 IFIT3, and IFIT5, to inhibit SARS-CoV-2 replication, suggesting this family plays an important role in 233 the restriction of SARS-CoV-2. RNA replication was also reduced by the RNA binding protein 234 SPAT2SL. Following stress stimuli, SPAT2SL is recruited to cytoplasmic stress granules, where viral 235 RNA can be sequestered to reduce viral genome synthesis (Miller, 2011; Zhu et al., 2008) . Finally, the 236 ISG DNAJC6, a member of the heat shock protein 40 (HSP40) family, was also determined to impact 237 the SARS-CoV-2 replicative stage (Fig 3B) . HSP40 family members are known to play critical roles in 238 protein transport, folding, and structural disassembly, and can bind the 3' untranslated region of the 239 mouse hepatitis virus (MHV) coronavirus (Nanda et al., 2003; Rosenzweig et al., 2019) . Overall, these 240 data suggest that molecular recognition and targeting of viral RNA is a critical host defense strategy 241 used to interfere with SARS-CoV-2 genome synthesis. translation. Specifically, NT5C3 was found to inhibit translation of HCV proteins, and ISG20 was shown 258 to interfere with translation of VSV by discriminating between self and non-self mRNAs (Metz et al., 8 ERAD. Accumulation of viral proteins during virion assembly at the ER-Golgi interface can trigger 262 ERAD. Accordingly, we found the ERAD regulator ERLIN1 to strongly attenuate late stages of SARS-263 CoV-2 replication. Two additional factors, RETREG1 and FNDC4, also involved in this pathway with 264 roles as a ER-phagy receptor and association with the aggresome (Wilkinson, 2019), were also found to 265 restrict SARS-CoV-2 replication, suggesting that ERAD is a critical cellular antiviral mechanism 266 triggered during SARS-CoV-2 infection. Vesicle Trafficking. Trans-Golgi vesicle budding was found as an enriched network for the control of 269 SARS-CoV-2 replication (Fig 2C) . Proteins within this network include the heat shock protein HSPA8, 270 and the 2',3'-cyclic nucleotide 3' phosphodiesterase CNP; both mapped to late stage viral replication 271 (Fig 3C) . HSPA8 is involved in vesicle uncoating, whereas CNP was reported to inhibit release of human The bone marrow stromal antigen 2 (BST2; also known as CD317 or tetherin) was identified as 281 a potent inhibitor of SARS-CoV-2 replication (Fig 3C) . BST2 traffics through the ER and Golgi, and 282 localizes at the plasma membrane and in endosomes. It has been shown to inhibit viral release of several 283 enveloped viruses, including HIV-1, human coronavirus 229E, and SARS-CoV-1, that either bud at the 284 plasma membrane or at the ERGIC by tethering their virions to the cell surface or intracellular 285 membranes (Neil et al., 2008; Taylor et al., 2015; Van Damme et al., 2008; Wang et al., 2014) . 286 287 BST2 restriction of SARS-CoV-2 replication was further confirmed in ACE2/TMPRSS2-288 expressing 293T and Huh7 cells at 24 and 48 h post-infection (Fig 5A, B, S2A) . We next conducted 289 loss-of-function studies in HeLa cells, since these harbor constitutive expression of BST2 (Neil et al., 290 2008; Van Damme et al., 2008) , and found that cells depleted for BST2 released significantly more 291 infectious viruses over time (Fig 5C, S2B) . Overall, these data strongly support a role for BST2 in the 292 restriction of SARS-CoV-2 replication. Notably, BST2 expression reduced SARS-CoV-2 RNA replication (53% reduction compared 295 to control cells) followed by a more potent reduction of viral release (74% reduction) (Fig 3B, C) . To 9 RNA replication (Siu et al., 2008) . We confirmed that this system can recapitulate virus egress, as 299 transfection of viral M, N, and E, but not E and N alone, resulted in secreted N protein (Fig S2C) . Using 300 this system, we detected a strong reduction of VLP release in the presence of BST2, evidenced by loss 301 of secreted N, corroborating that BST2 acts to inhibit egress of SARS-CoV-2 (Fig 5D) . We next 302 investigated if BST2 colocalizes with SARS-CoV-2 structural proteins. Notably, we detected 303 colocalization of BST2 and structural proteins M and S at intracellular foci within the perinuclear region 304 (caption 2, Fig 5E, S2D ) but not at the plasma membrane (caption 1, Fig 5E) . Together, these data 305 indicate that BST2 spatially associates with SARS-CoV-2 structural proteins during viral assembly and 306 trafficking. (Fig 6) . Interestingly, ten SARS-327 CoV-2 ISGs were found to reduce replication of four or more viruses (Fig 6) . These include well 328 described IFN signaling transducers, signaling molecules, and innate immune sensors STAT2, and 329 MYD88, inhibitors of viral entry IFITM2 and IFITM3 (Brass et al., 2009) , and viral nucleic acid binders 330 ZBP1 and IFIT1. Conversely, a cluster of 8 ISGs harbored selective activities for SARS-CoV-2 (Fig 6) , 331 including ER-Golgi resident proteins NAPA, APOL2, and ERLIN1. Notably, significant enrichment in 332 ISGs that regulate ER homeostasis and Golgi transport suggest that these organelles are critical sites for 333 the cellular control of SARS-CoV-2 replication. Surprisingly, many of these antiviral factors have not 334 been reported to impact other viruses that rely on these membraned compartments for replication and assembly, including flavi-, toga-, arteri-, and bunyaviruses, suggesting that these cellular defense 336 mechanisms target unique aspects of coronavirus translation, assembly, and egress. IFITM3 ZBP1 MYD88 IFITM2 STAT2 NRN1 BST2 RETREG1 JADE2 IFIT1 MSR1 FNDC4 NT5C3A ISG20 TMEM268 IFIT3 ETV6 TAGAP TENT5C TENT5A SPATS2L MAX CCND3 RAB27A UPP2 ST3GAL4 CLEC4D GBP3 B4GALT5 FZD5 ARNTL TRIM21 NAPA CRP APOL2 ERLIN1 CASP7 DDX60 manufacturer's instructions. HeLa-ACE2 cells were either transfected with equal amounts SARS-CoV-2 structural proteins HeLa-ACE2 cells were also transfected with 800 ng ORF7a-3xFLAG. 24 h post-transfection, cells were 721 washed briefly in 4°C PBS before incubation with ice-cold 4% paraformaldehyde (PFA The PFA was allowed to warm to RT as the cells were fixed for 20 minutes, the PFA was 723 removed and cells washed 3x in 1XPBS (5 min per wash). The fixed cells were quenched with 50 mM 724 Ammonium chloride (in PBS) for 5 minutes RT, washed 3 x in PBS, and permeabilized with 0 were stained overnight 728 with mouse anti-HM1.24 (BST-2) antibody (diluted 1:300 in 1% BSA in PBS) at 4°C. The following 729 day, the cells were washed 3x PBS and incubated with donkey anti-mouse-AlexaFluor-488 (1:400) for 730 2hr RT. The cells were washed 3x PBS (10 min per wash) and blocked with 2% BSA in PBS 731 supplemented with 5% normal mouse serum for 1 hr RT, briefly washed in 2% BSA, and incubated with 732 mouse anti-HA-Alexa-594 (1:200) and 4′,6-diamidino-2-phenylindole (DAPI), diluted to 1 µg/ml for 2 733 hr RT. Cells transfected with M-FLAG, E and N were stained overnight with mouse anti-BST-2 (diluted 734 1:300 in 1% BSA in PBS). The following day the cells were washed 3x PBS and incubated with donkey 735 anti-mouse-Rhodamine Venezuelan equine 827 encephalitis virus (VEEV), Yellow fever virus (YFV), Human parainfluenza virus type Newcastle disease virus (NDV), Respiratory syncytial virus (RSV) Equine viral arteritis